- Report
- July 2024
- 216 Pages
Global
From €1692EUR$1,859USD£1,437GBP
€2416EUR$2,655USD£2,052GBP
- Report
- December 2023
- 279 Pages
Global
From €2351EUR$2,583USD£1,997GBP
€3359EUR$3,690USD£2,853GBP
- Report
- March 2023
- 374 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- May 2022
- 213 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Report
- June 2021
- 209 Pages
Global
From €2365EUR$2,598USD£2,009GBP
€3379EUR$3,712USD£2,870GBP
- Book
- April 2022
- 496 Pages
- Book
- February 2012
- 408 Pages
- Book
- April 2019
- 216 Pages
United Kingdom
Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more